Skip to main content

Table 4 Adverse events in 26 systemic sclerosis patients treated with imatinib

From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Adverse event Number of patients %
Lower limb edema 5 19.2
Cough 5 19.2
Infections 5 19.2
Urticaria/rash 4 15.3
Arthritis 2 7.6
Transient creatine kinase elevation 1 3.8
Diarrhea 1 3.8
Thrombophlebitis 1 3.8
Others 4 15.3